AbbVie to Pay OSE Immunotherapeutics an Upfront Payment of $48M and Offer Potential Additional Milestone Payments of up to $665M

North Chicago, IL, and Nantes, France, February 28, 2024 (PRNewswire)  -- AbbVie and OSE Immunotherapeutics announced a partnership to advance OSE-230, a monoclonal antibody targeting chronic and severe inflammation.  Currently in the pre-clinical development phase, the collaboration helps AbbVie expand their immunology portfolio.

Read full article here.